secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2026-06-08T22:23:37+00:00
Accession:  0001193125-26-262264
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics stockholders elect three Class I directors and ratify auditor at 2026 annual meeting
--------------------------------------------------------------------------------

- All three Class I director nominees elected: Kabeer Aziz (13.5M for, 4.0M withheld), Gilbert Marks (15.9M for), Rob Readnour (15.9M for).
- Ratification of PricewaterhouseCoopers as auditor for fiscal 2026 approved with 22,724,674 for, 13 against, 16,848 abstain.
- Approximately 63.18% of outstanding shares (22.7M of 35.99M) represented at meeting, constituting quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/0001193125-26-262264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526262264/antx-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-262264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer